GLPwatch
Vision changes / NAION
5,283 FAERS reports across 10 drugs
Last updated 2026-07-12 06:04 UTCVision changes that happen suddenly and can include blurry or dim vision, or even partial loss of sight in one eye.
Plain-language definition of the term.
The FDA labels for Soliqua and Xultophy include 'Vision changes / NAION' in their Dosage and Administration sections, indicating a mention of this potential adverse effect.
AI summary of the sources below.
FAERS report counts (as of 2026Q2) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Ozempic | 1,494 | 2026Q2 |
| Trulicity | 1,371 | 2026Q2 |
| Mounjaro | 765 | 2026Q2 |
| Bydureon | 450 | 2026Q2 |
| Victoza | 373 | 2026Q2 |
| Wegovy | 341 | 2026Q2 |
| Zepbound | 247 | 2026Q2 |
| Soliqua | 143 | 2026Q2 |
| Rybelsus | 88 | 2026Q2 |
| Xultophy | 11 | 2026Q2 |
Mentioned in FDA labels
Research mentioning vision changes / naion (11)
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
- The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.
- Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.
- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.
- Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.
- Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.
- Blinded by the drug? A vigilyze signal linking semaglutide to NAION.
- Simultaneous Bilateral NAION Following Initiation of High-Dose Semaglutide: A Case Report.
- Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.
- Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.